CD248 deficiency promotes angiotensin II-induced aortic lesion by attenuating receptor stability in smooth muscle cells

Abstract

Background: Abdominal aortic aneurysm (AAA) is characterized by progressive dilation of the abdominal aorta that has a high prevalence of death due to aortic rupture. The hallmark of AAA is severe degeneration of the aortic media with the loss of vascular smooth muscle cells (VSMCs), the main source of extracellular matrix (ECM) proteins. CD248 was originally implicated in angiogenesis and tumourigenesis, but its role in the development of AAA remains unclear.

Methods: Mice lacking CD248 (Cd248^−/−) were generated and evaluated for angiotensin II (Ang II) and high-cholesterol diet feeding induced AAA. Loss-of-function approaches in A7r5 and C3H10T1/2 cells were used to study the involvement of CD248 in the Ang II signalling.

Results: CD248 expression was upregulated in the media and adventitia of patients and mice with aortic aneurysm. CD248 deficiency in mice exacerbates Ang II-induced aortic lesion along with severe disruption of elastic fibres and the VSMC layer. Interestingly, while compensatory ECM deposition was found in the aortic lesion of Cd248^−/− mice, collagen I content and p38 activation were significantly attenuated. Silencing of CD248 in VSMCs downregulated mitogen-activated protein kinase activation and ECM production. Loss of CD248 in VSMCs destabilized the membrane receptors for Ang II and platelet-derived growth factor (PDGF), and the C-terminal cytoplasmic domain of CD248 is apparently involved in this interaction.

Conclusions: The findings reveal that CD248 regulates the stability of the membrane receptors for Ang II and PDGF in VSMCs to transduce signals for collagen production in combating the loss of aortic wall strength during vascular remodelling.

Keywords

aortic aneurysm / vascular smooth muscle cells / collagen / angiotensin II receptors / PDGF receptors / CD248

References

[1] Cao RY, Amand T, Ford MD, Piomelli U, Funk CD. The murine angiotensin II-induced abdominal aortic aneurysm model: rupture risk and inflammatory progression patterns. Front Pharmacol. 2010; 1: 9.

[2] Kent KC, Zwolak RM, Egorova NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg. 2010; 52: 539-548.

[3] Lattanzi S. Abdominal aortic aneurysms: pathophysiology and clinical issues. J Intern Med. 2020; 288: 376-378.

[4] Trachet B, Fraga-Silva RA, Piersigilli A, et al. Dissecting abdominal aortic aneurysm in Ang II-infused mice: suprarenal branch ruptures and apparent luminal dilatation. Cardiovasc Res. 2015; 105: 213-222.

[5] Maegdefessel L, Azuma J, Toh R, et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest. 2012; 122: 497-506.

[6] Wilson JS, Baek S, Humphrey JD. Parametric study of effects of collagen turnover on the natural history of abdominal aortic aneurysms. Proc Math Phys Eng Sci. 2013; 469: 20120556.

[7] Liu B, Granville DJ, Golledge J, Kassiri Z. Pathogenic mechanisms and the potential of drug therapies for aortic aneurysm. Am J Physiol Heart Circ Physiol. 2020; 318: H652-H670.

[8] Rekhter MD. Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc Res. 1999; 41: 376-384.

[9] Teicher BA. CD248: a therapeutic target in cancer and fibrotic diseases. Oncotarget. 2019; 10: 993-1009.

[10] Khan KA, Mcmurray JL, Mohammed F, Bicknell R. C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation. FEBS J. 2019; 286: 3299-3332.

[11] Wu J, Zhang Q, Yang Z, et al. CD248-expressing cancer-associated fibroblasts induce non-small cell lung cancer metastasis via Hippo pathway-mediated extracellular matrix stiffness. J Cell Mol Med. 2024; 28: e70025.

[12] Hasanov Z, Ruckdeschel T, Konig C, et al. Endosialin promotes atherosclerosis through phenotypic remodeling of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2017; 37: 495-505.

[13] Tomkowicz B, Rybinski K, Sebeck D, et al. Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling. Cancer Biol Ther. 2014; 9: 908-915.

[14] Wilhelm A, Aldridge V, Haldar D, et al. CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism. Gut. 2016; 65: 1175-1185.

[15] Hong YK, Lee YC, Cheng TL, et al. Tumor endothelial marker 1 (TEM1/Endosialin/CD248) enhances wound healing by interacting with platelet-derived growth factor receptors. J Invest Dermatol. 2019; 139(10): 2204-2214.e7.

[16] Huang HP, Hong CL, Kao CY, et al. Gene targeting and expression analysis of mouse TEM1/endosialin using a lacZ reporter. Gene Expr Patterns. 2011; 11: 316-326.

[17] Daugherty A, Cassis LA, Lu H. Complex pathologies of angiotensin II-induced abdominal aortic aneurysms. J Zhejiang Univ Sci B. 2011; 12: 624-628.

[18] Upchurch GR, Schaub TA. Abdominal aortic aneurysm. Am Fam Physician. 2006; 73: 1200-1204.

[19] Sawada H, Lu HS, Cassis LA, Daugherty A. Twenty years of studying Ang II (angiotensin II)-Induced abdominal aortic pathologies in mice: continuing questions and challenges to provide insight into the human disease. Arterioscler Thromb Vasc Biol. 2022; 42: 277-288.

[20] Cao G, Xuan X, Hu J, Zhang R, Jin H, Dong H. How vascular smooth muscle cell phenotype switching contributes to vascular disease. Cell Commun Signal. 2022; 20: 180.

[21] Touyz RM, He G, El Mabrouk M, Schiffrin EL. p38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertens Pregnancy. 2001; 37: 574-580.

[22] Tai HC, Tsai PJ, Chen JY, et al. PPARγ level contributes to structural integrity and component production of elastic fibers in the aorta. Hypertension. 2016; 67: 1298-1308.

[23] Davis-Dusenbery BN, Wu C, Hata A. Micro-managing vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol. 2011; 31(11): 2370-2377.

[24] Di Benedetto P, Ruscitti P, Liakouli V, Del Galdo F, Giacomelli R, Cipriani P. Linking myofibroblast generation and microvascular alteration: the role of CD248 from pathogenesis to therapeutic target. Mol Med Rep. 2019; 20: 1488-1498.

[25] Zhan Y, Kim S, Izumi Y, et al. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol. 2003; 23: 795-801.

[26] Hu X, Wu T, Wang C, Li J, Ying C. CD248+CD8+ T lymphocytes suppress pathological vascular remodeling in human thoracic aortic aneurysms. Exp Biol Med. 2020; 0: 1-9.

[27] Harrison M, Naylor AJ, Apta B, Monaco C, Buckley CD, Rainger GE. Crosstalk between CD248 and PDGFR? Regulates the pathogenic role of smooth muscle cells in atherosclerosis. Atherosclerosis. 2015; 241: e45.

[28] O'shannessy DJ, Dai H, Mitchell M, et al. Endosialin and associated protein expression in soft tissue sarcomas: a potential target for anti-endosialin therapeutic strategies. Sarcoma. 2016; 2016: 5213628.

[29] Naylor AJ, Mcgettrick HM, Maynard WD, et al. A differential role for CD248 (endosialin) in PDGF-mediated skeletal muscle angiogenesis. PLoS One. 2014; 9: e107146.

[30] Maia M, Devriese A, Janssens T, et al. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer. 2011; 11: 162.

[31] Ritter SL, Hall RA. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol. 2009; 10: 819-830.

[32] Maudsley S, Zamah AM, Rahman N, et al. Platelet-derived growth factor receptor association with Na⁺/H⁺ exchanger regulatory factor potentiates receptor activity. Mol Cell Biol. 2000; 20(22): 8352-8363.

[33] Doyle DA, Lee A, Lewis J, Kim E, Sheng M, Mackinnon R. Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell. 1996; 85: 1067-1076.

[34] Valdez Y, Maia M, Conway EM. CD248: reviewing its role in health and disease. Curr Drug Targets. 2012; 13: 432-439.

[35] Hong YK, Cheng TL, Hsu CK, et al. Regulation of matrix reloading by tumor endothelial marker 1 protects against abdominal aortic aneurysm. Int J Biol Sci. 2024; 20: 3691-3709.

[36] Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res. 2007; 101: 441-454.

[37] Lu G, Su G, Davis JP, et al. A novel chronic advanced stage abdominal aortic aneurysm murine model. J Vasc Surg. 2017; 66: 232-242 e234.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.